
1. malar j. 2015 dec 16;14:504. doi: 10.1186/s12936-015-1018-3.

evaluation artemether-lumefantrine efficacy treatment uncomplicated 
malaria association pfmdr1, pfatpase6 k13-propeller
polymorphisms luanda, angola.

kiaco k(1)(2), teixeira j(3), machado m(4)(5), rosário v(6), lopes d(7).

author information: 
(1)unidade de parasitologia médica, instituto de higiene e medicina tropical,
universidade nova de lisboa, rua da junqueira 100, 1349-008, lisbon, portugal.
kinanga.kiaco@ihmt.unl.pt.
(2)serviços de saúde das forças armadas angolanas, estado maior general das
forças armadas, luanda, angola. kinanga.kiaco@ihmt.unl.pt.
(3)unidade de parasitologia médica, instituto de higiene e medicina tropical,
universidade nova de lisboa, rua da junqueira 100, 1349-008, lisbon, portugal.
joanafpteixeira@hotmail.com.
(4)unidade de parasitologia médica, instituto de higiene e medicina tropical,
universidade nova de lisboa, rua da junqueira 100, 1349-008, lisbon, portugal.
martamachado@medicina.ulisboa.pt.
(5)global health tropical medicine (ghtm), instituto de higiene e medicina
tropical, universidade nova de lisboa, rua da junqueira 100, 1349-008, lisbon,
portugal. martamachado@medicina.ulisboa.pt.
(6)unidade de parasitologia médica, instituto de higiene e medicina tropical,
universidade nova de lisboa, rua da junqueira 100, 1349-008, lisbon, portugal.
virgilio.do.rosario@gmail.com.
(7)global health tropical medicine (ghtm), instituto de higiene e medicina
tropical, universidade nova de lisboa, rua da junqueira 100, 1349-008, lisbon,
portugal. dferreira@ihmt.unl.pt.

background: drug resistance plasmodium falciparum posed obstacle to
effective treatment challenges many malaria control programmes endemic
areas. angola, 2003, chloroquine (cq) used first-line therapy for
uncomplicated malaria. replaced initially amodiaquine and, 2006, 
artemisinin-based combination therapy (act) artemether-lumefantrine (al,
coartem(®)). efficacy study act, conducted angola 2004 2005,
showed baseline efficacy ≈99%.
methods: 103 malaria patients enrolled according proceedings.
patients followed clinical parasitological evaluations 28
days, parasite density identification evaluated microscopy, pfmsp2
were genotyped nested-pcr, distinguish parasite recrudescence new
infections; polymorphisms codons 86 1246 pfmdr1 gene, 769 of
pfatp6 gene assessed pcr-rflp sequencing pfk13-propeller
genotype.
results: cure rate 91.3%. obtained results showed 103
patients, 12.6% (n = 13) still parasitaemia 1 day treatment was
finished. day 0, 94 evaluated samples, wild-type alleles were
identified 73.4% (n = 69) pfmdr1 n86y position one sample carried
the mutant allele (y) pfmdr1 1246; 14% samples showed increased
pfmdr1 copy number; 100% (n = 21) wild-type allele k13 gene the
studied positions.
discussion: results showed changes parasite profile susceptibility al
in comparison baseline data 2002 2004 genotyping
characteristics; clinical outcome treatment al link a
particular genotype treatment failure; observed changes provide
sufficient evidence treatment policy change, suggest a
carefully monitoring needed area.

doi: 10.1186/s12936-015-1018-3 
pmcid: pmc4681156
pmid: 26670642  [indexed medline]

